Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00847210 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00847210 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 36 participants.
The verdict
NCT00847210, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to asses the pharmacokinetics and safety of dexlansoprazole modified release (MR), once daily (QD), in adolescent subjects (age 12-17 years old) with Symptomatic Gastroesophageal Reflux Disease.
Interventions
- DRUG Dexlansoprazole MR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2009-05 |
| Est. Completion | 2009-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00847210
The ClinicalTrials.gov registry entry for NCT00847210 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dexlansoprazole MR is the first listed.
NCT00847210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00847210 about?
NCT00847210 is a clinical study titled "Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease". The purpose of this study is to asses the pharmacokinetics and safety of dexlansoprazole modified release (MR), once daily (QD), in adolescent subjects (age 12-17 years old) with Symptomatic Gastroesophageal Reflux Disease.
What is the current status of trial NCT00847210?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2009-05. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00847210?
The interventions under investigation include: Dexlansoprazole MR (DRUG).
Who is sponsoring clinical trial NCT00847210?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.